Not Yet RecruitingPhase 4ACTRN12606000428561

Pharmacokinetics of 0.25% levobupivacaine with adrenaline following caudal epidural administration in children


Sponsor

Royal Childrens' Hospital

Enrollment

50 participants

Start Date

Nov 2, 2006

Study Type

Interventional

Conditions

Summary

Brief Synopsis Levobupivacaine, the S(-) enantiomer of racemic bupivacaine, has been shown to be less cardiotoxic than racemic bupivacaine and its R(+) enantiomer while retaining equipotent local anaesthetic properties, and is commonly used by paediatric anaesthetists. The pharmacokinetics of levobupivacaine in children under 2 years of age (1), and of children less than 3 months of age (2) after caudal epidural blockade have been published; pharmacokinetics in children after levobupivacaine administration via lumbar epidural catheter and ilioinguinal nerve block have also been examined (3, 4). Adrenaline is commonly added to local anaesthetic solutions, both to provide a marker of inadvertent intravascular injection of solution, and with the intention to induce vasoconstriction thereby reducing the rate of systemic absorption of local anaesthetic (resulting in both lower peak plasma levels and therefore potential for toxicity, and longer duration of local anaesthetic effect). The pharmacokinetics of levobupivacaine administered with adrenaline have not been examined. We propose a study of the pharmacokinetics of levobupivacaine when administered via the caudal epidural route, with the addition of adrenaline. We plan to enroll 50 subjects up to 18 years of age undergoing elective sub-umbilical surgical procedures for which caudal epidural analgesia is indicated. Subjects will receive 2mg/kg levobupivacaine, as a 0.25% solution with adrenaline 5 mcg/mL (1:200 000), via the caudal route, under general anaesthesia. Peripheral venous blood samples will be taken from a dedicated intravenous catheter inserted at the time of surgery. Up to 5 blood samples per subject will be taken in the period up to six hours post caudal injection. Samples will be assayed for plasma levobupivacaine. Analysis of raw data will use a population, rather than individual, pharmacokinetic model (NONMEM), allowing accurate estimation of population parameters from data taken from a small number of subjects, and allowing inclusion of incomplete sample data from individual subjects (5). Sample timing is not crucial where this form of analysis is used, so proposed sampling times need not be strictly adhered to.


Eligibility

Sex: Both males and femalesMax Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study measures how a local anesthetic called levobupivacaine is processed in children's bodies after it is given through a caudal epidural injection (in the lower back) during surgery. Children under 18 who are having surgery below the belly button and would normally receive caudal analgesia can participate.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Adrenaline 1:200000 will be used as an adjuvant with levobupivacaine 0.25% for single shot caudal epidural analgesia in children. Plasma levobupivacaine levels will be assayed at random times in the f

Adrenaline 1:200000 will be used as an adjuvant with levobupivacaine 0.25% for single shot caudal epidural analgesia in children. Plasma levobupivacaine levels will be assayed at random times in the first six hours following the single caudal injection. Results will be analysed using a population pharmacokinetic model (NONMEM) to assess the impact of adrenaline on plasma levels of levobupivacaine.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000428561